
    
      Single centre, open-label, randomised, three-way crossover study in 12 healthy volunteers.
      The study consisted of three 8-day treatment periods separated by washout periods of 10-15
      days. On each of the treatment periods the volunteers received either a daily oral dose of
      BIA 2-093 900 mg once-daily (od), BIA 2-093 450 mg twice-daily (bid), or Oxcarbazepine
      (TrileptalÂ®) 450 mg bid.
    
  